Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyorin Pharmaceutical Co's other current liabilities for the quarter that ended in Mar. 2026 was 円11,027 Mil.
Kyorin Pharmaceutical Co's quarterly other current liabilities
declined
from Sep. 2025 (円10,889 Mil) to Dec. 2025 (円10,720 Mil) but then
increased
from Dec. 2025 (円10,720 Mil) to Mar. 2026 (円11,027 Mil).
Kyorin Pharmaceutical Co's annual other current liabilities
declined
from Mar. 2024 (円9,916 Mil) to Mar. 2025 (円8,683 Mil) but then
increased
from Mar. 2025 (円8,683 Mil) to Mar. 2026 (円11,027 Mil).
Kyorin Pharmaceutical Co Other Current Liabilities Related Terms
Kyorin Pharmaceutical Co Other Current Liabilities Historical Data
* Premium members only.
The historical data trend for Kyorin Pharmaceutical Co's Other Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyorin Pharmaceutical Co Other Current Liabilities Chart
Kyorin Pharmaceutical Co Other Current Liabilities Calculation
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of 円11,027 Mil mean?
Kyorin Pharmaceutical Co (TSE:4569) has a Other Current Liabilities of 円11,027 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kyorin Pharmaceutical Co.
Is Kyorin Pharmaceutical Co's Other Current Liabilities too high?
Kyorin Pharmaceutical Co's current Other Current Liabilities is 円11,027 Mil. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Other Current Liabilities compare to ZTS and UTHR?
Kyorin Pharmaceutical Co's Other Current Liabilities of 円11,027 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kyorin Pharmaceutical Co. Kyorin Pharmaceutical Co's current Other Current Liabilities is 円11,027 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,582.96, compared to a current price of 円1,167.00 — trading 26.3% below its estimated fair value. The current Other Current Liabilities is 円11,027 Mil. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Other Current Liabilities is 円11,027 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,167.00 is trading 26.3% below its estimated GF Value™ of 円1,582.96.
GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4569:
Other Current Liabilities: 円11,027 Mil
GF Value™: 円1,582.96 vs. price of 円1,167.00 (26.3% below fair value)
No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for TSE:4569
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4569 has been successfully added to your 
